| HOME >> MEDICINE >> TECHNOLOGY |
NEW YORK, Nov. 17, 2010 /PRNewswire/ -- See video from Merck and Co., Inc at:
Researchers today presented results from the Phase III DEFINE (Determining the EFficacy and Tolerability of CETP INhibition with AnacEtrapib) study with Merck's investigational CETP inhibitor, anacetrapib. In the trial of 1,623 patients with coronary heart disease (CHD) or CHD risk equivalents, anacetrapib showed no significant differences from placebo in the primary safety measures studied. There were no significant differences in mean changes in blood pressure between the anacetrapib and placebo treatment groups, nor were there any significant differences in serum electrolytes or aldosterone levels. During the 76-week treatment phase, the pre-specified adjudicated cardiovascular endpoint (defined as cardiovascular death, myocardial infarction, unstable angina or stroke) occurred in 16 anacetrapib-treated patients (2.0 percent) compared with 21 placebo-treated patients (2.6 percent) (p=0.40). At 24 weeks, anacetrapib decreased LDL-C by 40 percent (from 81 to 45 mg/dl vs. 82 to 77 mg/dl for placebo, p<0.001) and increased HDL-C by 138 percent (from 40 to 101 mg/dl vs. 40 to 46 mg/dl for placebo, p<0.001) in patients already treated with a statin and at guideline-recommended LDL-C goal. The DEFINE data were presented today at the American Heart Association Scientific Sessions and published concurrently online in the New England Journal of Medicine. Available content includes soundbites and b-roll.
About thenewsmarket.com
thenewsmarket.com delivers free broadcast- and streaming-quality video and multimedia content directly to media around the world, 24/7. More than 25,000 media outlets in 190+ countries use thenewsmarket.com, including the AP, BBC, CNBC, CNN, France 24, N24, nytimes.com, RAI, TVE, ZDF and a lot more.
Registered journalists can preview and download video, audio, text, graphics and photos at http://www.thenewsmarket.com.
If not already registered, please take a moment to sign up - registration is quick, easy and free: http://www.thenewsmarket.com/registration
We are always happy to receive your feedback, suggestions or enquiries. Email us on journalisthelp@thenewsmarket.com
Story Id: 20566
'/>"/>
| SOURCE thenewsmarket.com Copyright©2010 PR Newswire. All rights reserved |
Related medicine technology :
1. VIDEO from International Osteoporosis Foundation available on thenewsmarket.com: IOF Focuses on WHO Fracture Risk Assessment Tool for International Discussions
2. Shrink Nanotechnologies Unveils Videos of StemDisc450 Prototype Growing Human Embryonic Stem Cells
3. VIDEO From thenewsmarket.com and Lundbeck: Lundbeck Continues Strong Growth in Third Quarter
4. VIDEO from thenewsmarket.com and Novartis: Novartis drug Afinitor® Approved by FDA as First Medication for Children and Adults With a Benign Brain Tumor Associated With Tuberous Sclerosis
5. VIDEO from thenewsmarket.com and Roche Pharmaceuticals: MabThera Approved in Europe for First Line Maintenance Treatment of Follicular Lymphoma, a Common Type of Blood Cancer
6. VIDEO From thenewsmarket.com and AstraZeneca: AstraZeneca Announces Third Quarter and Nine Months Results 2010
7. VIDEO From thenewsmarket.com and Novartis: Phase III Data Show That Novartis Meningococcal Vaccine Menveo® Demonstrated Robust Immunogenicity in Infants
8. Generex Reschedules Live Video Webcast
9. Aircraft Medical Launches Worlds First Low Cost Video Laryngoscope
10. New Manhattan Research Report Explores the Growing Consumer Demand for Online Health Video and How Pharma Marketers Can Leverage this Format
11. New Study: Physician Adoption of Live Video Detailing Has Doubled Since 2008, But Will Likely Plateau Until 2012 as Pharma Optimizes Targeting
| Copyright © 2003-2012 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |